Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Notified Body BSI Sets Out Clear Post-Brexit Paths As It Goes Dutch

Executive Summary

BSI tackles Brexit issues head-on with aim to allay fears and bring clarity while UK regulator, MHRA, remains reticent to do so. Its messages are relevant for all doing business in the UK

You may also be interested in...



Brexit Trade Deal Must Wait, But UK Medtech Sector Finds Reasons To Be Cheerful

During the week of the ostensibly pivotal EU Summit on Brexit, the UK government has made the EU27 wait for its white paper on proposed post-EU trading arrangements. The UK medtech industry, in turn, is kept waiting on its EU future. But far from remaining idle, manufacturers are focusing on innovation adoption and working with the NHS, where there is a new sense of purpose, and maybe a light at the end of the tunnel.

Brexit Points Of Order: Hard Brexit Plans Nearer As UK Remains Vague On Device-Sector Impact

The latest round of EU Brexit negotiations were bruising encounters for the UK, whose perceived selective approach to EU membership was rebuffed again. The talks coincided with the restatement of the government's position on device- and pharma-related Brexit issues. UK medtechs may well be looking at the June EU Council meeting as the point of no return.

Reading Between The Lines: Is There A Positive Message Hidden In MDCG’s Blame Document?

The hope is now that a new EU document will be issued to address head on the scale of bottlenecks at notified bodies and of products needing to be removed from the market.

Topics

Latest News
UsernamePublicRestriction

Register

MT122731

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel